Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Icahn School of Medicine at Mount Sinai
The primary objectives of this study are to:
1. Establish the phenotype and frequency of circulating immune cell compartments in patients undergoing treatment with Sipuleucel-T.
2. Determine the induction and the quality of prostate antigen-specific T cell immunity in patients undergoing treatment with Sipuleucel-T.
3. Correlate whole-blood RNA transcript-based signatures with clinical outcomes in patients treated with Sipuleucel-T.
4. Evaluate the cytokine and chemokine milieu in the peripheral blood pre- and post-treatment with Sipuleucel-T.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18 years of age
Written informed consent obtained
Patients with castration-resistant prostate cancer who are initiating Sipuleucel-T as standard therapy
No prior systemic chemotherapy for metastatic prostate cancer
Hemoglobin \> 9 mg/dl
You may not be if
Patients unable to understand the research protocol and/or provide informed consent
